In a big achievement for the Hyderabad-based Bharat Biotech, Hungary’s National Institute of Pharmacy and Nutrition awarded the GMP certificate for the manufacturing of Covaxin.
“Another milestone in our account as COVAXIN® receives GMP certificate from Hungary. This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatories”, Bharat Biotech posted on the microblogging platform Twitter.
The company also announced that it would be applying in many other countries for the emergency use authorisation.
Covaxin is also expected to get EUA form WHO at the end of the month.
“With this approval Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines at Global quality standards and moving forward in the ongoing fight against the COVID-19 pandemic”, the company noted in a press release.
It further noted “The recognition compliments the firm's commitment of driving world class innovation and being a frontrunner in the research and development of vaccines.”
Covaxin is being administered in the country since the world’s largest vaccination drive against Covid-19 started in India in January this year.
Bharat Biotech is currently supplying about 2.5 crore doses of the vaccine per month which is expected to rise to 5 crores per month.
